Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 6/20 | 0.64 |
| ▸ | GBA1 | P04062 | 7/20 | 0.48 |
| ▸ | APP | P05067 | 2/20 | 0.48 |
| ▸ | PDE5A | O76074 | 2/20 | 0.44 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.39 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.39 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22249447 | 0.90 | NLRP3 (0.67) | NLRP3APPPDE5ACYP1A2CYP3A4 | |
| SCHEMBL20651894 | 0.84 | NLRP3 (0.46) | NLRP3GBA1PDE5ACYP2E1CYP2A6 | |
| SCHEMBL22249504 | 0.82 | NLRP3 (0.64) | NLRP3APPCYP1A2CYP3A4 | |
| SCHEMBL22249410 | 0.82 | NLRP3 (0.69) | NLRP3APP | |
| SCHEMBL22249577 | 0.81 | NLRP3 (0.75) | NLRP3APP | |
| SCHEMBL23513877 | 0.80 | NLRP3 (0.77) | NLRP3APPTLR7 | |
| SCHEMBL22249404 | 0.80 | NLRP3 (0.73) | NLRP3APPPDE5ACYP1A2 | |
| SCHEMBL22249556 | 0.80 | NLRP3 (0.81) | NLRP3APPTLR7 | |
| SCHEMBL22249557 | 0.79 | NLRP3 (0.79) | NLRP3GBA1APPTLR7CYP1A2 | |
| SCHEMBL22249490 | 0.79 | NLRP3 (0.72) | NLRP3APPPDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220089571-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2022-03-24 | — | — | US | disclosed |
| WO-2020150113-A1 | SUBSTITUTED QUINAZOLINES AS NLRP3 MODULATORS, FOR USE IN THE TREATMENT OF CANCER | INNATE TUMOR IMMUNITY, INC. (US) | 2020-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089571-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, PYCARD | NLRP3 1/4885GBA1 2729/4885APP 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.